Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial

Patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer and primary resistance to trastuzumab have a poor clinical outcome and lack good evidence to inform clinical decision. This study investigated the efficacy and safety of pyrotinib plus capecitabine in this...

Full description

Saved in:
Bibliographic Details
Published in:BMC medicine 2023-08, Vol.21 (1), p.300-300, Article 300
Main Authors: Cao, Jun, Teng, Yuee, Li, Huiping, Zhang, Lili, Ouyang, Quchang, Xie, Weimin, Pan, Yueyin, Song, Zhenchuan, Ling, Xiaoling, Wu, Xiaohong, Xu, Jingwei, Li, Li, Ren, Liping, Wang, Hong, Zhou, Dongxian, Luo, Jing, Hu, Xichun
Format: Article
Language:English
Subjects:
Breast cancer
Cancer therapies
Capecitabine
Clinical medicine
Clinical trials
Confidence intervals
Creatinine
Diarrhea
Disease control
Drug dosages
Drug resistance
Effectiveness
Epidermal growth factor
ErbB-2 protein
Growth factors
Health services
Human epidermal growth factor receptor 2
Kinases
Metastasis
Monoclonal antibodies
Patients
Pertuzumab
Prevention
Pyrotinib
Survival
Targeted cancer therapy
Toxic diseases
Toxicity
Trastuzumab
Trastuzumab resistance
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer and primary resistance to trastuzumab have a poor clinical outcome and lack good evidence to inform clinical decision. This study investigated the efficacy and safety of pyrotinib plus capecitabine in this population. This phase 2 trial was conducted at 16 sites in China. Patients received oral pyrotinib 400 mg once daily and capecitabine 1000 mg/m twice a day on days 1-14 of each 21-day cycle until disease progression or intolerable toxicity. The primary endpoint was investigator-assessed progression-free survival (PFS). Between June 2019 and September 2021, 100 patients were enrolled with a median age of 51 years (range, 24-69). All patients had been treated with trastuzumab and 21 (21.0%) patients had prior use of pertuzumab. As of August 31, 2022, the median follow-up duration was 20.1 months (range, 1.3-38.2). The median PFS was 11.8 months (95% confidence interval [CI], 8.4-15.1), which crossed the pre-specified efficacy boundary of 8.0 months. The objective response rate was 70.0% (70/100), with a median duration of response of 13.8 months (95% CI, 10.2-19.3). The disease control rate was 87.0% (87/100). The median overall survival was not reached. The most common grade ≥ 3 treatment-emergent adverse event was diarrhea (24 [24.0%]). No treatment-related deaths occurred. Pyrotinib plus capecitabine can be considered to be a treatment option in HER2-positive advanced breast cancer patients who have shown primary resistance to trastuzumab. Even in the era of modern anti-HER2 treatments, this clinical setting warrants more investigations to meet unmet needs. ClinicalTrials.gov, NCT04001621. Retrospectively registered on June 28, 2019.
ISSN:1741-7015
1741-7015
DOI:10.1186/s12916-023-02999-0